CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Oyster Point Pharma, Inc. - OYST CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Oyster Point Pharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 11.12
Open* 11.13
1-Year Change* -39.18%
Day's Range* 11.12 - 11.14
52 wk Range 3.46-19.98
Average Volume (10 days) 429.94K
Average Volume (3 months) 6.72M
Market Cap 299.85M
P/E Ratio -100.00K
Shares Outstanding 26.84M
Revenue 19.58M
EPS -6.64
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 22, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low
Dec 30, 2022 11.14 0.00 0.00% 11.14 11.16 11.09
Dec 29, 2022 11.12 -0.02 -0.18% 11.14 11.15 11.12
Dec 28, 2022 11.13 0.02 0.18% 11.11 11.15 11.11
Dec 27, 2022 11.14 0.04 0.36% 11.10 11.15 11.09
Dec 23, 2022 11.09 0.04 0.36% 11.05 11.15 10.99
Dec 22, 2022 11.14 0.10 0.91% 11.04 11.14 11.03
Dec 21, 2022 11.05 -0.01 -0.09% 11.06 11.10 11.03
Dec 20, 2022 11.04 -0.03 -0.27% 11.07 11.09 11.04
Dec 19, 2022 11.04 -0.06 -0.54% 11.10 11.10 11.04
Dec 16, 2022 11.09 -0.01 -0.09% 11.10 11.16 11.07
Dec 15, 2022 11.12 0.01 0.09% 11.11 11.14 11.09
Dec 14, 2022 11.14 0.05 0.45% 11.09 11.15 11.08
Dec 13, 2022 11.09 0.00 0.00% 11.09 11.10 11.06
Dec 12, 2022 11.07 -0.02 -0.18% 11.09 11.10 11.02
Dec 9, 2022 11.09 0.00 0.00% 11.09 11.11 11.08
Dec 8, 2022 11.08 -0.01 -0.09% 11.09 11.10 11.08
Dec 7, 2022 11.09 0.00 0.00% 11.09 11.16 11.08
Dec 6, 2022 11.10 0.01 0.09% 11.09 11.11 11.08
Dec 5, 2022 11.08 -0.05 -0.45% 11.13 11.14 11.08
Dec 2, 2022 11.09 0.00 0.00% 11.09 11.17 11.09

Oyster Point Pharma, Inc. Events

Time (UTC) Country Event
Wednesday, November 8, 2023

Time (UTC)

21:00

Country

US

Event

Q3 2023 Oyster Point Pharma Inc Earnings Release
Q3 2023 Oyster Point Pharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 24.539 0 0 0 0
Total Operating Expense 121.194 70.989 47.301 16.736 6.86
Selling/General/Admin. Expenses, Total 95.435 31.178 13.673 2.981 2.051
Research & Development 24.234 39.811 33.628 13.755 3.632
Unusual Expense (Income) 0 1.177
Operating Income -96.655 -70.989 -47.301 -16.736 -6.86
Interest Income (Expense), Net Non-Operating -3.734 0 1.59 0.233 0.259
Net Income Before Taxes -100.659 -70.52 -45.711 -16.503 -6.601
Net Income After Taxes -100.659 -70.52 -45.711 -16.503 -6.601
Net Income Before Extra. Items -100.659 -70.52 -45.711 -16.503 -6.601
Net Income -100.659 -70.52 -45.711 -16.503 -6.601
Total Adjustments to Net Income 0 -12.543
Income Available to Common Excl. Extra. Items -100.659 -70.52 -45.711 -16.503 -19.144
Income Available to Common Incl. Extra. Items -100.659 -70.52 -45.711 -16.503 -19.144
Diluted Net Income -100.659 -70.52 -45.711 -16.503 -19.144
Diluted Weighted Average Shares 26.0365 24.1286 21.3669 20.6123 20.6123
Diluted EPS Excluding Extraordinary Items -3.86607 -2.92267 -2.13933 -0.80064 -0.92877
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -3.86607 -2.92267 -2.13933 -0.80064 -0.87166
Other, Net -0.27 0.469
Revenue 24.539
Cost of Revenue, Total 1.525
Gross Profit 23.014
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 2.704 6.596 17.943 0 0
Total Operating Expense 44.915 45.537 34.711 22.026 18.92
Selling/General/Admin. Expenses, Total 39.898 38.55 28.497 15.296 13.092
Research & Development 4.681 5.462 6.214 6.73 5.828
Operating Income -42.211 -38.941 -16.768 -22.026 -18.92
Other, Net -2.615 -0.513 0.222 0.01 0.011
Net Income Before Taxes -47.892 -42.064 -17.67 -22.016 -18.909
Net Income After Taxes -47.892 -42.064 -17.67 -22.016 -18.909
Net Income Before Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
Net Income -47.892 -42.064 -17.67 -22.016 -18.909
Income Available to Common Excl. Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
Income Available to Common Incl. Extra. Items -47.892 -42.064 -17.67 -22.016 -18.909
Diluted Net Income -47.892 -42.064 -17.67 -22.016 -18.909
Diluted Weighted Average Shares 26.6316 26.1929 26.038 25.9899 25.9241
Diluted EPS Excluding Extraordinary Items -1.79832 -1.60593 -0.67862 -0.8471 -0.7294
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.79832 -1.60593 -0.67862 -0.8471 -0.7294
Revenue 2.704 6.596 17.943
Interest Income (Expense), Net Non-Operating -3.066 -2.61 -1.124
Cost of Revenue, Total 0.336 1.525
Gross Profit 2.368 5.071
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 215.25 196.367 142.18 5.618 23.174
Cash and Short Term Investments 193.372 192.585 139.147 5.228 22.311
Cash 5.228 22.311
Prepaid Expenses 9.075 3.782 3.033 0.39 0.863
Total Assets 222.617 197.91 143.209 5.704 23.174
Property/Plant/Equipment, Total - Net 5.399 1.482 0.978 0.066 0
Other Long Term Assets, Total 1.082 0.061 0.051 0.02 0
Total Current Liabilities 28.802 10.982 5.399 0.94 2.067
Accounts Payable 6.496 2.279 0.5 0.462 0.418
Accrued Expenses 22.29 8.685 4.899 0.478 1.649
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 123.08 11.251 5.911 0.946 2.067
Total Long Term Debt 89.819 0.019 0 0 0
Other Liabilities, Total 4.459 0.25 0.512 0.006 0
Total Equity 99.537 186.659 137.298 4.758 21.107
Redeemable Preferred Stock 0 0 0
Preferred Stock - Non Redeemable, Net 0 43.001 43.001
Common Stock 0.027 0.026 0.021 0.004 0.004
Additional Paid-In Capital 354.92 341.384 221.508 0.273 0.119
Retained Earnings (Accumulated Deficit) -255.41 -154.751 -84.231 -38.52 -22.017
Total Liabilities & Shareholders’ Equity 222.617 197.91 143.209 5.704 23.174
Total Common Shares Outstanding 26.5796 25.8905 21.3669 20.6123 20.6123
Cash & Equivalents 193.372 192.585 139.147
Property/Plant/Equipment, Total - Gross 5.636 1.578 0.997
Accumulated Depreciation, Total -0.237 -0.096 -0.019
Current Port. of LT Debt/Capital Leases 0.016 0.018
Capital Lease Obligations 0.004 0.019
Total Receivables, Net 6.656
Accounts Receivable - Trade, Net 6.656
Total Inventory 6.086
Other Current Assets, Total 0.061
Long Term Investments 0.886
Long Term Debt 89.815
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 167.354 215.25 189.686 158.886 182.648
Cash and Short Term Investments 143.364 193.372 184.166 154.805 175.91
Cash & Equivalents 143.364 193.372 184.166 154.805 175.91
Prepaid Expenses 14.099 9.075 3.02 4.081 6.738
Total Assets 176.72 222.617 195.009 161.503 184.772
Property/Plant/Equipment, Total - Net 5.257 5.399 2.627 2.526 2.033
Other Long Term Assets, Total 3.223 1.082 2.696 0.091 0.091
Total Current Liabilities 23.026 28.802 15.161 9.471 13.736
Accounts Payable 2.596 6.496 3.506 2.332 7.093
Accrued Expenses 20.399 22.29 11.638 7.121 6.625
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.031 0.016 0.017 0.018 0.018
Total Liabilities 120.727 123.08 57.497 9.719 14.124
Total Long Term Debt 90.666 89.819 41.926 0.011 0.015
Capital Lease Obligations 0.03 0.004 0.007 0.011 0.015
Other Liabilities, Total 7.035 4.459 0.41 0.237 0.373
Total Equity 55.993 99.537 137.512 151.784 170.648
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.027 0.027 0.026 0.026 0.026
Additional Paid-In Capital 359.268 354.92 350.832 347.434 344.282
Retained Earnings (Accumulated Deficit) -303.302 -255.41 -213.346 -195.676 -173.66
Total Liabilities & Shareholders’ Equity 176.72 222.617 195.009 161.503 184.772
Total Common Shares Outstanding 26.6627 26.5796 26.0942 26.0064 25.9608
Total Receivables, Net 5.736 6.656 2.5
Long Term Debt 90.636 89.815 41.919
Accounts Receivable - Trade, Net 5.736 6.656
Total Inventory 4.094 6.086
Other Current Assets, Total 0.061 0.061
Long Term Investments 0.886 0.886
Property/Plant/Equipment, Total - Gross 5.568
Accumulated Depreciation, Total -0.311
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -100.659 -70.52 -45.711 -16.503 -6.601
Cash From Operating Activities -89.37 -58.399 -40.815 -17.083 -4.674
Non-Cash Items 13.639 6.973 3.266 0.154 1.081
Changes in Working Capital -2.491 5.071 1.611 -0.734 0.846
Cash From Investing Activities -1.485 -0.7 -0.2 0 0
Capital Expenditures -1.485 -0.7 -0.2 0 0
Cash From Financing Activities 91.642 112.547 174.985 0 26.175
Financing Cash Flow Items -4.947 -0.361 0 0
Issuance (Retirement) of Stock, Net 96.589 112.908 174.985 0 21.875
Issuance (Retirement) of Debt, Net 0 4.3
Net Change in Cash 0.787 53.448 133.97 -17.083 21.501
Cash From Operating Activities 0.141 0.077 0.019
Cash Interest Paid 2.352
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -47.892 -100.659 -58.595 -40.925 -18.909
Cash From Operating Activities -49.705 -89.37 -47.895 -37.085 -16.53
Cash From Operating Activities 0.074 0.141 0.091 0.055 0.023
Non-Cash Items 8.222 13.639 8.696 5.728 2.68
Changes in Working Capital -10.109 -2.491 1.913 -1.943 -0.324
Cash From Investing Activities -0.085 -1.485 -1.25 -0.994 -0.34
Capital Expenditures -0.085 -1.485 -1.25 -0.994 -0.34
Cash From Financing Activities -0.218 91.642 40.726 0.299 0.195
Financing Cash Flow Items -0.087 -4.947 -0.03 -0.023 -0.023
Issuance (Retirement) of Stock, Net 0.076 96.589 0.605 0.322 0.218
Net Change in Cash -50.008 0.787 -8.419 -37.78 -16.675
Issuance (Retirement) of Debt, Net -0.207 40.151
Cash Interest Paid 2.067 2.352

Oyster Point Pharma, Inc. Company profile

About Oyster Point Pharma Inc

Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Oyster Point Pharma Inc revenues increased from $0K to $24.5M. Net loss increased 43% to $100.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase of 33% to $33.5M (expense), Stock-based Compensation in SGA increase of 22% to $7.3M (expense).

Industry: Biotechnology & Medical Research (NEC)

202 Carnegie Center
Suite 106
PRINCETON
NEW JERSEY 08540
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

BTC/USD

26,680.30 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

89.95 Price
+0.690% 1D Chg, %
Long position overnight fee 0.0349%
Short position overnight fee -0.0568%
Overnight fee time 21:00 (UTC)
Spread 0.030

ETH/USD

1,596.06 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

XRP/USD

0.52 Price
+0.670% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading